Alibaba (BABA) Pays $600 Million to Settle DOJ Drug Probe

Alibaba Group Holding (NYSE:BABA), the Chinese e commerce and cloud computing giant behind Alibaba.com and AliExpress, has agreed to pay 600 million dollars to settle Justice Department allegations that it and its payment affiliate failed to stop illegal pharmaceutical sales moving through their platforms. Shares fell 1.89 percent to 96.14 dollars on the news.

The company acknowledged responsibility for roughly 80,000 prohibited transactions tied to U.S. bound imports between January 2016 and December 2024, with a combined gross merchandise value exceeding 200 million dollars. Federal agents made more than 40 undercover purchases of banned pharmaceuticals and pill press equipment to build the case, according to the Justice Department.

At a Glance

• BABA trades at 96.14 dollars, down 1.89 percent on the day
• Market cap stands at 230.70 billion dollars
• 52 week range spans 91.99 to 146.87 dollars
• Dividend yield sits at 1.09 percent, RSI reads 24.03

Inside the Settlement

Alibaba's portion of the penalty breaks down into 125 million dollars in criminal fines and 200 million dollars in forfeiture. AUS Merchant Services, the payment processor formerly known as Alipay U.S. and now a subsidiary of Ant Group, will pay 85 million dollars in fines plus 190 million in forfeited funds. Prosecutors said internal employees had raised concerns about the platform's safeguards even as rules against restricted goods stayed on the books, and that a private messaging tool on the marketplace was used by some sellers to arrange illicit deals, occasionally steering buyers toward encrypted apps outside the platform.

On the payments side, investigators found that wire transfer records were not always fed into AUS Merchant Services' monitoring systems, which let suspicious activity from high risk regions slip past detection. One seller reportedly kept shipping banned goods even after the company had flagged and reported the account. Both firms agreed to non prosecution deals that require compliance overhauls and continued cooperation with federal authorities.

Alibaba Valuation, Momentum and Yield

The stock's RSI of 24.03 places it deep in oversold territory, a reading that often draws attention from traders looking for a bounce after a sharp selloff. Shares now sit closer to the low end of their 52 week band of 91.99 to 146.87 dollars, reflecting how far sentiment has pulled back from last year's highs.

The bull case rests on Alibaba's scale: a 230.70 billion dollar market cap, a 1.09 percent dividend yield, and a business that still commands enormous e commerce and cloud infrastructure across China and beyond. Investors willing to look past legal headlines might see the settlement as a one time cost that clears uncertainty rather than an ongoing drag.

The bear case centers on regulatory exposure. An 80,000 transaction violation record spanning nearly a decade raises questions about how quickly compliance fixes can be verified, and further scrutiny from U.S. or Chinese regulators remains a live risk. The P/E and EPS figures were not disclosed in the available data, leaving valuation judgments reliant on the price and cap figures at hand.

What Happens to Alibaba's Compliance Overhaul Now

Both companies now face the task of proving their new safeguards actually work, with prosecutors watching for continued cooperation under the terms of the agreements. Whether the settlement marks a clean break or the start of deeper scrutiny into how global marketplaces police illegal goods remains an open question for regulators and investors alike.